<< Back to Educational Activities
Learn More & View Event »
On-Demand Programs
Show : Per page of 1
Considerations for Risk Stratification, Evaluation of Currently Available Therapies, and Examining Bispecific Antibodies in Development for Relapsed/Refractory Setting of Multiple Myeloma
This enduring educational activity will focus primarily on risk stratification and best practices to more accurately inform treatment sequencing in patients with relapsed/refractory multiple myeloma; explore mechanisms of action of innovative therapies for multiple myeloma; and evaluate new and emerging bispecific anti-BCMA and anti-FcRH5 clinical trial data in the setting of relapsed/refractory multiple myeloma.
RELEASED DATE: April 26, 2024
EXPIRATION DATE: April 26, 2025
